Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals


  • Products Id :- GDHC0528MD
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the six months.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2018 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2018 11

2.2.1 GlaxoSmithKline to Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 12

2.2.2 Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 12

2.2.3 Sanofi Prices Public Offering Notes for USD9.9 Billion 13

2.2.4 Platinum Equity to Acquire LifeScan from Johnson & Johnson for USD2.1 Billion 13

2.2.5 Valeant Pharma Prices Private Placement of 9.25% Senior Notes Due 2026 for USD1.17 Billion 13

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2018 14

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2018 15

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 16

3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2018 16

3.1.1 Top M&A Deals in March 2018 17

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2017-March 2018 18

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2018 19

3.2.1 Top Equity Offering Deals in March 2018 20

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2017-March 2018 21

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2018 22

3.3.1 Top PE/VC Deals in March 2018 23

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2018 24

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2018 25

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-March 2018 26

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-March 2018 27

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2018 28

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2017-March 2018 29

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USUSD m), March 2018 30

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2018 31

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 32

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2017-March 2018 33

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USUSD m), October 2017-March 2018 34

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 35

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2018 36

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2018 36

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USUSD m), March 2018 37

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USUSD m), October 2017-March 2018 38

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USUSD m), October 2017-March 2018 39

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USUSD m), October 2017-March 2018 40

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USUSD m), October 2017-March 2018 42

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2018 43

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2018 43

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2018 44

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 45

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2018 45

5.1.1 Oncology-Deals of the Month 46

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2018 48

5.2.1 Central Nervous System-Deals of the Month 49

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2018 51

5.3.1 Infectious Diseases-Deals of the Month 52

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2018 53

5.4.1 Cardiovascular-Deal of the Month 54

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2018 55

5.5.1 Immunology-Deals of the Month 56

5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, March 2018 57

5.6.1 Respiratory-Deal of the Month 58

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2018 59

5.7.1 Metabolic Disorders-Deals of the Month 60

6 Deal Summary by Geography 61

6.1 Pharmaceuticals & Healthcare, North America Deals, March 2018 61

6.1.1 North America-Deals of the Month 62

6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2018 63

6.2.1 Europe-Deals of the Month 64

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2018 65

6.3.1 Asia-Pacific-Deals of the Month 66

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2018 67

6.4.1 Rest of the World-Deals of the Month 68

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 69

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2017-March 2018 69

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2017-March 2018 70

8 Further Information 71

8.1 Methodology 71

8.2 About GlobalData 72

8.3 Contact Us 72

8.4 Disclosure information 72

8.5 Disclaimer 73

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2018 14

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2018 15

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 16

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USUSD m), by Therapy Area, October 2017-March 2018 18

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 19

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 21

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 22

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), by Therapy Area, October 2017-March 2018 24

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2018 25

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2018 25

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 26

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 28

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 29

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 30

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 32

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017-March 2018 33

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017-March 2018 34

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 35

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 36

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 37

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 38

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 39

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2017-March 2018 40

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USUSD m), October 2017-March 2018 40

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USUSD m), March 2018 42

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 45

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 48

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 51

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 53

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 55

Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 57

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 59

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 61

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 63

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 65

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 67

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 69

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 70

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2018 11

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2018 15

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 17

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2018 17

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USUSD m), by Therapy Area, October 2017-March 2018 18

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 20

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2018 20

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 21

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 23

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2018 23

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2017-March 2018 24

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2018 26

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 27

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2017-March 2018 27

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 28

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 29

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 30

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USUSD m), March 2018 31

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 32

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017-March 2018 34

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USUSD m), October 2017-March 2018 35

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 36

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USUSD m), October 2017-March 2018 37

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 38

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USUSD m), March 2018 39

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2017-March 2018 41

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USUSD m), March 2018 42

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2018 43

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2018 43

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2018 44

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 46

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 49

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 52

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 54

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 56

Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 58

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 60

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 62

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 64

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 66

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 68

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 69

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USUSD m), October 2017-March 2018 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license
Single User License
USD 1000 INR 70980
Site License
USD 2000 INR 141960
Corporate User License
USD 3000 INR 212940

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com